Merit Medical Systems, Inc. MMSI
87.50
0.20
0.23%
as of 25 Sep
- Market cap
- $5.2B
- P/E
- 35.7×
Follow MMSI
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
41.41 | 40.62 | 29.33 | 28.30 |
P/S ratio |
3.34 | 3.44 | 2.66 | 2.62 | |
P/FCF ratio |
24.19 | 24.53 | 18.87 | 20.72 | |
P/Operating CF |
65.76 | 52.93 | 100.83 | 59.73 | |
P/B ratio |
3.22 | 3.29 | 2.52 | 2.46 | |
Price to Tangible BV |
10.20 | 9.66 | 6.71 | 7.84 | |
EV/Sales |
3.57 | 3.63 | 2.82 | 2.81 | |
EV/EBITDA |
17.27 | 16.94 | 13.23 | 12.92 | |
EV/Operating CF |
19.71 | 18.51 | 14.63 | 15.63 | |
EV/FCF |
25.88 | 25.90 | 20.02 | 22.17 | |
Quick Ratio |
2.72 | 2.82 | 3.32 | 2.66 | |
Current Ratio |
4.28 | 4.34 | 5.08 | 4.20 | |
Net Debt/EBITDA |
4.35 | 3.20 | 3.13 | 3.00 | |
Debt/Assets |
27.86% | 27.33% | 27.04% | 25.71% | |
Debt/Equity |
0.48 | 0.46 | 0.45 | 0.44 | |
Asset Turnover |
0.59 | 0.59 | 0.59 | 0.58 | |
Operating CF/Net income |
2.70 | 2.59 | 0.99 | 1.79 | |
Capex/Depreciation |
(0.66) | (0.71) | (0.48) | (0.51) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
6.24% | 6.74% | 5.92% | 6.06% | |
Selling, General and Administrative Expense of Revenue |
31.19% | 29.15% | 30.95% | 30.85% | |
Intangible Assets out of Total Assets |
0.40 | 0.39 | 0.37 | 0.40 | |
Share Based Compensation of Revenue |
3.54% | 2.51% | 2.35% | 3.08% | |
Graham Net Nets |
(0.02) | (0.01) | 0.00 | (0.02) | |
Graham Number |
34.17 | 36.16 | 38.02 | 39.39 | |
Earnings Yield |
2.41% | 2.46% | 3.41% | 3.53% | |
Free Cash Flow Yield |
4.13% | 4.08% | 5.30% | 4.83% | |
Revenue per Share |
6.48 | 6.66 | 6.42 | 7.02 | |
Operating CF per Share |
1.27 | 1.67 | 0.68 | 1.16 | |
Capex per Share |
(0.40) | (0.43) | (0.28) | (0.30) | |
Free Cash Flow per Share |
0.87 | 1.24 | 0.40 | 0.86 | |
Cash per Share |
6.62 | 7.55 | 8.20 | 7.52 | |
Shareholders Equity per Share |
25.82 | 26.78 | 27.34 | 28.15 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
25.82 | 26.78 | 27.34 | 28.15 | |
Free Cash Flow |
51.56 | 73.20 | 23.92 | 51.09 | |
Working Capital |
755.06 | 800.39 | 884.90 | 847.31 | |
Capital Expenditures |
(23.42) | (25.31) | (16.77) | (18.19) | |
Net Current Asset Value |
(116.06) | (61.46) | 9.22 | (71.58) | |
EV/EBIT |
31.57 | 29.80 | 23.17 | 22.00 | |
Capex to Sales |
0.06 | 0.06 | 0.04 | 0.04 | |
Net Profit Margin |
7.22% | 9.65% | 10.74% | 9.26% | |
Price to Operating Income |
29.51 | 28.23 | 21.84 | 20.55 | |
| Other line items | |||||
Average Receivables |
226.36 | 220.50 | 226.10 | 241.86 | |
Average Payables |
62.78 | 64.53 | 65.81 | 69.90 | |
Average Inventory |
318.54 | 319.88 | 335.16 | 348.71 | |
Average Assets |
2,504.54 | 2,552.26 | 2,593.63 | 2,724.83 | |
Average Common Equity |
1,426.41 | 1,481.83 | 1,527.58 | 1,583.93 |
Columns are period end dates